Banque Cantonale Vaudoise Sells 4,596 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Banque Cantonale Vaudoise lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 37.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,779 shares of the medical research company’s stock after selling 4,596 shares during the period. Banque Cantonale Vaudoise’s holdings in IQVIA were worth $1,844,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. PGGM Investments raised its holdings in shares of IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. raised its stake in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Quadrature Capital Ltd bought a new stake in IQVIA during the first quarter valued at approximately $3,365,000. Raymond James & Associates increased its holdings in shares of IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares during the last quarter. Finally, Versor Investments LP purchased a new stake in shares of IQVIA during the 3rd quarter valued at $1,328,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research reports. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. TD Cowen reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, Truist Financial cut their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $194.38 on Thursday. The business has a 50 day moving average of $224.22 and a 200 day moving average of $227.56. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a market cap of $35.28 billion, a PE ratio of 25.51, a P/E/G ratio of 1.98 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.